Shifting the dogma about synovial lining macrophages: the early drivers of rheumatoid arthritis
24 May 2023
Insights into a specific macrophage population suggest that these cells could drive inflammation in rheumatoid arthritis. Understanding their complex role could lead to better treatments for patients.
New hope for patients after vedolizumab found effective to treat Chronic Pouchitis
31 March 2023
A new study led by Oxford researchers has found vedolizumab can induce remission in patients who have chronic pouchitis after surgery for ulcerative colitis.
New approach to nail bed injury surgery could significantly cut NHS costs
30 March 2023
According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.
Fat tissues can play a protective role against inflammation in the intestine
22 February 2023
A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.
Communication at the crossroads of the immune system
6 February 2023
In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.
New drug offers hope for people with hand osteoarthritis
22 December 2022
A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.
Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease
16 November 2022
Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.
MRC funding awarded to Kennedy researchers
8 September 2022
Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.
Breakthrough in treatment for Dupuytren’s disease
30 April 2022
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.
New research suggests targeting blood vessels could be key to controlling fibrotic disease
1 April 2022
By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.
Defining the role of resident memory B cells in the fight against influenza
31 March 2022
Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
23 March 2022
The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.
Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself
11 January 2022
A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.
A drug being trialled to treat cancer, could be the key to reducing gut inflammation
19 November 2021
Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity
Large genetic study suggests shared biological processes cause irritable bowel syndrome and anxiety
5 November 2021
An international study of more than 50,000 people with irritable bowel syndrome (IBS) has revealed that IBS symptoms may be caused by the same biological processes as conditions such as anxiety. The research highlights the close relationship between brain and gut health and paves the way for development of new treatments.
New therapeutic targets identified to treat inflammatory bowel disease
22 October 2021
Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.
Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age
15 October 2021
A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.
Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells
26 July 2021
Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.
Exploring the link between joint injury and osteoarthritis
25 June 2021
A new study published in The Lancet Rheumatology shows potential ways to predict how likely someone is to develop osteoarthritis after a knee injury.
Repurposed drug can induce remission of inflammatory arthritis
20 May 2021
Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.